Relay Therapeutics (RLAY) Stock Forecast, Price Target & Predictions
RLAY Stock Forecast
Relay Therapeutics stock forecast is as follows: an average price target of $18.00 (represents a 332.69% upside from RLAY’s last price of $4.16) and a rating consensus of 'Buy', based on 9 wall street analysts offering a 1-year stock forecast.
RLAY Price Target
The average price target for Relay Therapeutics (RLAY) is $18.00 based on 1-year price targets from 9 Wall Street analysts in the past 3 months, with a price target range of $20.00 to $16.00. This represents a potential 332.69% upside from RLAY's last price of $4.16.
RLAY Analyst Ratings
According to 9 Wall Street analysts, Relay Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for RLAY stock is 1 'Strong Buy' (11.11%), 7 'Buy' (77.78%), 1 'Hold' (11.11%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Relay Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 16, 2024 | Robert Burns | H.C. Wainwright | $19.00 | $7.60 | 150.00% | 356.73% |
| Sep 10, 2024 | Akash Tewari | Jefferies | $16.00 | $9.51 | 68.24% | 284.62% |
| Sep 09, 2024 | Peter Lawson | Barclays | $17.00 | $9.51 | 78.76% | 308.65% |
| Sep 04, 2024 | Jason Gerberry | Bank of America Securities | $20.00 | $6.41 | 212.01% | 380.77% |
| May 10, 2024 | Peter Lawson | Barclays | $15.00 | $6.68 | 124.66% | 260.58% |
| May 06, 2024 | Matt Biegler | Oppenheimer | $25.00 | $7.04 | 255.11% | 500.96% |
| Apr 20, 2023 | Akash Tewari | Jefferies | $12.50 | $12.35 | 1.21% | 200.48% |
| Feb 03, 2023 | Oppenheimer | $33.00 | $22.76 | 44.99% | 693.27% | |
| Sep 30, 2022 | Peter Lawson | Barclays | $23.00 | $23.14 | -0.61% | 452.88% |
The latest Relay Therapeutics stock forecast, released on Sep 16, 2024 by Robert Burns from H.C. Wainwright, set a price target of $19.00, which represents a 150.00% increase from the stock price at the time of the forecast ($7.60), and a 356.73% increase from RLAY last price ($4.16).
Relay Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 6 |
| Avg Price Target | - | - | $18.67 |
| Last Closing Price | $4.16 | $4.16 | $4.16 |
| Upside/Downside | -100.00% | -100.00% | 348.80% |
In the current month, the average price target of Relay Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Relay Therapeutics's last price of $4.16. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 14, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 16, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 09, 2024 | Oppenheimer | Buy | Perform | Downgrade |
| Sep 09, 2024 | Barclays | Overweight | Overweight | Hold |
| Sep 04, 2024 | Bank of America Securities | Buy | Buy | Hold |
| Aug 07, 2024 | Oppenheimer | Buy | Buy | Hold |
| Aug 07, 2024 | JMP Securities | Underperform | Underperform | Hold |
| Jul 17, 2024 | JMP Securities | Underperform | Underperform | Hold |
| Jul 17, 2024 | Oppenheimer | Market Outperform | Market Outperform | Hold |
| Jun 07, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Jun 07, 2024 | Oppenheimer | Market Outperform | Market Outperform | Hold |
| May 10, 2024 | Oppenheimer | Market Outperform | Market Outperform | Hold |
| May 06, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Apr 20, 2023 | Citigroup | Buy | Overweight | Upgrade |
| Apr 20, 2023 | Piper Sandler | Neutral | Downgrade | |
| Apr 20, 2023 | Wolfe Research | Underperform | Downgrade | |
| Apr 20, 2023 | Craig-Hallum | Buy | Upgrade | |
| Apr 20, 2023 | Barclays | Equal-Weight | Downgrade | |
| Apr 20, 2023 | Jefferies | Hold | Buy | Upgrade |
| Apr 20, 2023 | Jefferies | Hold | Upgrade | |
| Apr 19, 2023 | Raymond James | Outperform | Strong Buy | Upgrade |
| Apr 13, 2023 | Raymond James | Outperform | Initialise | |
| Feb 03, 2023 | Oppenheimer | Outperform | Initialise | |
| Sep 12, 2022 | Citigroup | Buy | Upgrade |
Relay Therapeutics's last stock rating was published by H.C. Wainwright on Oct 14, 2024. The company gave RLAY a "Buy" rating, the same as its previous rate.
Relay Therapeutics Financial Forecast
Relay Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $25.20M | $119.00K | $226.00K | $253.00K | $344.00K | $365.00K | $419.00K | $567.00K | $666.00K | $844.00K | $952.00K | $82.65M |
| Avg Forecast | $2.04M | $33.33K | $50.00K | $50.00K | $6.76M | $88.89K | $88.89K | $120.00K | $581.82K | $374.55K | $741.67K | $128.00K | $271.43K | $1.80M | $2.08M | $166.67K | $3.84M | $107.14K | $6.67M | $3.39M | $36.67M |
| High Forecast | $2.04M | $33.33K | $50.00K | $50.00K | $22.25M | $88.94K | $88.94K | $121.50K | $1.08M | $377.04K | $741.67K | $128.00K | $271.43K | $1.80M | $2.08M | $166.67K | $3.84M | $107.14K | $6.67M | $3.39M | $36.67M |
| Low Forecast | $2.04M | $33.33K | $50.00K | $50.00K | $89.01K | $88.83K | $88.83K | $118.50K | $215.49K | $372.05K | $741.67K | $128.00K | $271.43K | $1.80M | $2.08M | $166.67K | $3.84M | $107.14K | $6.67M | $3.39M | $36.67M |
| # Analysts | 1 | 1 | 1 | 3 | 7 | 3 | 1 | 1 | 3 | 12 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 9 |
| Surprise % | - | - | - | - | - | - | - | - | - | 67.29% | 0.16% | 1.77% | 0.93% | 0.19% | 0.18% | 2.51% | 0.15% | 6.22% | 0.13% | 0.28% | 2.25% |
Relay Therapeutics's average Quarter revenue forecast for Dec 23 based on 3 analysts is $581.82K, with a low forecast of $215.49K, and a high forecast of $1.08M. RLAY's average Quarter revenue forecast represents a -97.69% decrease compared to the company's last Quarter revenue of $25.20M (Sep 23).
Relay Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 7 | 3 | 1 | 1 | 3 | 12 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 9 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-73.58M | $-106.05M | $-101.18M | $-93.94M | $-78.33M | $-76.45M | $-70.94M | $-66.42M | $-59.82M | $-192.44M | $-41.27M | $36.19M |
| Avg Forecast | $-1.07M | $-17.55K | $-26.32K | $-26.32K | $-3.56M | $-46.79K | $-46.79K | $-57.04M | $-306.28K | $-197.17K | $-390.43K | $-61.00M | $-57.82M | $-947.56K | $-1.10M | $-65.24M | $-2.02M | $-56.40K | $-3.51M | $-42.12M | $-19.30M |
| High Forecast | $-1.07M | $-17.55K | $-26.32K | $-26.32K | $-46.85K | $-46.76K | $-46.76K | $-45.63M | $-113.44K | $-195.85K | $-390.43K | $-48.80M | $-46.26M | $-947.56K | $-1.10M | $-52.20M | $-2.02M | $-56.40K | $-3.51M | $-33.70M | $-19.30M |
| Low Forecast | $-1.07M | $-17.55K | $-26.32K | $-26.32K | $-11.71M | $-46.82K | $-46.82K | $-68.45M | $-567.19K | $-198.48K | $-390.43K | $-73.20M | $-69.39M | $-947.56K | $-1.10M | $-78.29M | $-2.02M | $-56.40K | $-3.51M | $-50.55M | $-19.30M |
| Surprise % | - | - | - | - | - | - | - | - | - | 373.17% | 271.62% | 1.66% | 1.62% | 82.67% | 69.71% | 1.09% | 32.86% | 1060.62% | 54.83% | 0.98% | -1.87% |
6 analysts predict RLAY's average Quarter EBITDA for Mar 21 to be $-42.12M, with a high of $-33.70M and a low of $-50.55M. This is -216.41% lower than Relay Therapeutics's previous annual EBITDA (Dec 20) of $36.19M.
Relay Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 7 | 3 | 1 | 1 | 3 | 12 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 9 |
| Net Income | - | - | - | - | - | - | - | - | - | $-65.73M | $-98.50M | $-87.30M | $-43.31M | $-87.26M | $-75.16M | $-51.48M | $-67.46M | $-60.83M | $-193.40M | $-42.18M | $35.28M |
| Avg Forecast | $-89.75M | $-90.15M | $-87.74M | $-84.34M | $-79.98M | $-108.24M | $-102.75M | $-58.62M | $-100.71M | $-115.69M | $-114.35M | $-62.69M | $-58.72M | $-93.71M | $-83.30M | $-67.05M | $-74.24M | $-81.29M | $-59.58M | $-43.06M | $22.36M |
| High Forecast | $-89.75M | $-90.15M | $-87.74M | $-74.97M | $-52.87M | $-108.24M | $-102.75M | $-46.89M | $-92.76M | $-93.39M | $-114.35M | $-50.15M | $-46.98M | $-93.71M | $-83.30M | $-53.64M | $-74.24M | $-81.29M | $-59.58M | $-34.45M | $22.36M |
| Low Forecast | $-89.75M | $-90.15M | $-87.74M | $-93.71M | $-96.24M | $-108.24M | $-102.75M | $-70.34M | $-104.68M | $-125.45M | $-114.35M | $-75.23M | $-70.47M | $-93.71M | $-83.30M | $-80.46M | $-74.24M | $-81.29M | $-59.58M | $-51.68M | $22.36M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.57% | 0.86% | 1.39% | 0.74% | 0.93% | 0.90% | 0.77% | 0.91% | 0.75% | 3.25% | 0.98% | 1.58% |
Relay Therapeutics's average Quarter net income forecast for Mar 21 is $-43.06M, with a range of $-51.68M to $-34.45M. RLAY's average Quarter net income forecast represents a -222.07% decrease compared to the company's last Quarter net income of $35.28M (Dec 20).
Relay Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 7 | 3 | 1 | 1 | 3 | 12 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 9 |
| SG&A | - | - | - | - | - | - | - | - | - | $18.48M | $20.12M | $19.58M | $16.37M | $16.07M | $17.46M | $16.07M | $15.55M | $14.68M | $14.42M | $12.73M | $15.54M |
| Avg Forecast | $29.02M | $474.14K | $711.22K | $711.22K | $96.09M | $1.26M | $1.26M | $1.71M | $8.28M | $5.33M | $10.55M | $1.82M | $3.86M | $25.60M | $29.63M | $2.37M | $54.62M | $1.52M | $94.83M | $48.23M | $521.56M |
| High Forecast | $29.02M | $474.14K | $711.22K | $711.22K | $316.51M | $1.27M | $1.27M | $1.73M | $15.33M | $5.36M | $10.55M | $1.82M | $3.86M | $25.60M | $29.63M | $2.37M | $54.62M | $1.52M | $94.83M | $48.23M | $521.56M |
| Low Forecast | $29.02M | $474.14K | $711.22K | $711.22K | $1.27M | $1.26M | $1.26M | $1.69M | $3.07M | $5.29M | $10.55M | $1.82M | $3.86M | $25.60M | $29.63M | $2.37M | $54.62M | $1.52M | $94.83M | $48.23M | $521.56M |
| Surprise % | - | - | - | - | - | - | - | - | - | 3.47% | 1.91% | 10.75% | 4.24% | 0.63% | 0.59% | 6.78% | 0.28% | 9.63% | 0.15% | 0.26% | 0.03% |
Relay Therapeutics's average Quarter SG&A projection for Dec 23 is $8.28M, based on 3 Wall Street analysts, with a range of $3.07M to $15.33M. The forecast indicates a -55.23% fall compared to RLAY last annual SG&A of $18.48M (Sep 23).
Relay Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 7 | 3 | 1 | 1 | 3 | 12 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 9 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.00 | $-0.00 | $-0.72 | $-0.36 | $-0.79 | $-0.69 | $-0.48 | $-0.66 | $-0.66 | $-2.10 | $-0.47 | $0.50 |
| Avg Forecast | $-0.64 | $-0.64 | $-0.63 | $-0.60 | $-0.57 | $-0.77 | $-0.73 | $-0.73 | $-0.72 | $-0.82 | $-0.82 | $-0.69 | $-0.70 | $-0.71 | $-0.63 | $-0.62 | $-0.56 | $-0.61 | $-0.45 | $-0.49 | $0.17 |
| High Forecast | $-0.64 | $-0.64 | $-0.63 | $-0.53 | $-0.38 | $-0.77 | $-0.73 | $-0.73 | $-0.66 | $-0.67 | $-0.82 | $-0.69 | $-0.70 | $-0.71 | $-0.63 | $-0.62 | $-0.56 | $-0.61 | $-0.45 | $-0.49 | $0.17 |
| Low Forecast | $-0.64 | $-0.64 | $-0.63 | $-0.67 | $-0.69 | $-0.77 | $-0.73 | $-0.73 | $-0.75 | $-0.89 | $-0.82 | $-0.69 | $-0.70 | $-0.71 | $-0.63 | $-0.62 | $-0.56 | $-0.61 | $-0.45 | $-0.49 | $0.17 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.00% | 0.00% | 1.04% | 0.51% | 1.12% | 1.10% | 0.78% | 1.18% | 1.08% | 4.68% | 0.97% | 2.94% |
According to 6 Wall Street analysts, Relay Therapeutics's projected average Quarter EPS for Mar 21 is $-0.49, with a low estimate of $-0.49 and a high estimate of $-0.49. This represents a -198.10% decrease compared to RLAY previous annual EPS of $0.50 (Dec 20).
Relay Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BDTX | Black Diamond Therapeutics | $2.50 | $20.00 | 700.00% | Buy |
| CCCC | C4 Therapeutics | $4.05 | $20.00 | 393.83% | Buy |
| IPSC | Century Therapeutics | $1.17 | $5.00 | 327.35% | Buy |
| RLAY | Relay Therapeutics | $4.50 | $18.00 | 300.00% | Buy |
| ARVN | Arvinas | $19.10 | $58.50 | 206.28% | Buy |
| CGEM | Cullinan Oncology | $11.49 | $34.00 | 195.91% | Buy |
| TERN | Terns Pharmaceuticals | $6.80 | $18.67 | 174.56% | Buy |
| FHTX | Foghorn Therapeutics | $5.51 | $14.00 | 154.08% | Buy |
| PLRX | Pliant Therapeutics | $14.37 | $35.50 | 147.04% | Buy |
| MLYS | Mineralys Therapeutics | $12.35 | $30.00 | 142.91% | Buy |
| STOK | Stoke Therapeutics | $12.10 | $26.50 | 119.01% | Buy |
| APLS | Apellis Pharmaceuticals | $34.53 | $70.80 | 105.04% | Buy |
| AMLX | Amylyx Pharmaceuticals | $4.28 | $8.25 | 92.76% | Buy |
| DAWN | Day One Biopharmaceuticals | $12.64 | $24.00 | 89.87% | Buy |
| NRIX | Nurix Therapeutics | $21.18 | $32.67 | 54.25% | Buy |
| EWTX | Edgewise Therapeutics | $30.17 | $46.25 | 53.30% | Buy |
| BPMC | Blueprint Medicines | $96.48 | $122.60 | 27.07% | Buy |